Nathan Roscoe

Statistics

Publications

Citations

102

H-Index

Active since

2019

Affiliations

Navidea Biopharmaceuticals (United States)(Current)

The University of Texas MD Anderson Cancer Center

Nathan Roscoe is an author at Navidea Biopharmaceuticals (United States) specializing in oncology, cancer immunology, and tumor-infiltrating lymphocytes.

Publications per year

2019–2021

Publications

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program

Ling Li, Ruifang Sun, Yi Miao et al. · Modern Pathology · 2019 · 55 citations · Full text

Medicine, Hematology, Oncology +17

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

Ulrich Jaeger, Michael Bishop, Gilles Salles et al. · Blood · 2020 · 31 citations

Life Sciences, Hematology, Oncology +17

Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma

Eileen Shiuan, Anupama Reddy, Stephanie O. Dudzinski et al. · Cancers · 2021 · 16 citations · Full text

Medicine, Immunology, Oncology +17

1–3 of 3